PapersFlow Research Brief
Sinusitis and nasal conditions
Research Guide
What is Sinusitis and nasal conditions?
Sinusitis and nasal conditions refer to a group of disorders including chronic rhinosinusitis and nasal polyps characterized by inflammation of the sinonasal mucosa, often involving eosinophilia, microbiome alterations, and impacting quality of life.
The field encompasses 72,148 papers on chronic rhinosinusitis, nasal polyps, inflammation, biologics, eosinophilia, sinus microbiome, treatment guidelines, endoscopic surgery, quality of life, and immunopathology. "European Position Paper on Rhinosinusitis and Nasal Polyps 2020" by Fokkens et al. (2020) provides evidence-based recommendations on diagnosis and treatment, noting rhinosinusitis as a significant health problem with large societal financial burden. "Psychometric validity of the 22‐item Sinonasal Outcome Test" by Hopkins et al. (2009) validates the SNOT-22 instrument for assessing health-related quality of life in chronic rhinosinusitis patients.
Topic Hierarchy
Research Sub-Topics
Chronic Rhinosinusitis Pathophysiology
Researchers study inflammatory pathways, epithelial barrier dysfunction, and cytokine profiles in chronic rhinosinusitis (CRS) subtypes using tissue biopsies and omics analyses. They elucidate endotype-specific mechanisms driving persistence and severity.
Biologics Chronic Rhinosinusitis Nasal Polyps
Clinical trials evaluate monoclonal antibodies targeting IL-4, IL-5, and IgE (e.g., dupilumab, mepolizumab) for severe CRS with nasal polyps, assessing efficacy, safety, and biomarkers for patient selection. Real-world studies track long-term outcomes.
Endoscopic Sinus Surgery Outcomes
Investigations analyze functional endoscopic sinus surgery (FESS) techniques, revision rates, and complications in CRS cohorts using registries and RCTs. They develop imaging-guided and navigation-enhanced procedures for complex anatomy.
Sinus Microbiome Dysbiosis
Metagenomic studies profile bacterial communities in CRS sinuses, linking dysbiosis (e.g., Corynebacterium dominance) to inflammation and treatment response via 16S sequencing and culturomics. Researchers test microbiome-modulating therapies.
Patient-Reported Outcomes Rhinosinusitis
Validation and application of instruments like SNOT-22 and NOSE scales measure symptom burden, quality of life, and treatment impacts in CRS trials. Studies correlate PROs with objective endoscopy and CT scores.
Why It Matters
Sinusitis and nasal conditions impose substantial health and economic burdens, as outlined in "European Position Paper on Rhinosinusitis and Nasal Polyps 2020" by Fokkens et al. (2020), which details evidence-based management strategies for chronic rhinosinusitis and nasal polyps. Biologics like dupilumab demonstrate efficacy in severe cases, with "Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52)" by Bachert et al. (2019) reporting results from two phase 3 trials showing improved outcomes over placebo. Validated tools such as the SNOT-22 from "Psychometric validity of the 22‐item Sinonasal Outcome Test" by Hopkins et al. (2009) and NOSE scale from "Development and Validation of the Nasal Obstruction Symptom Evaluation (NOSE) Scale" by Stewart et al. (2004) enable precise measurement of patient symptoms and treatment effects in otorhinolaryngology practice. Staging systems in "Staging in rhinosinusitus" by Lund and Mackay (1993) and "Staging for Rhinosinusitis" by Lund and Kennedy (1997) guide endoscopic surgery decisions.
Reading Guide
Where to Start
"European Position Paper on Rhinosinusitis and Nasal Polyps 2020" by Fokkens et al. (2020) serves as the starting point because it provides comprehensive evidence-based definitions, diagnostic criteria, and treatment recommendations with 5368 citations.
Key Papers Explained
"European Position Paper on Rhinosinusitis and Nasal Polyps 2020" by Fokkens et al. (2020) updates "EPOS 2012: European position paper on rhinosinusitis and nasal polyps 2012. A summary for otorhinolaryngologists" by Fokkens et al. (2012), which itself revises earlier 2007 guidelines, adding definitions for difficult-to-treat cases. "Psychometric validity of the 22‐item Sinonasal Outcome Test" by Hopkins et al. (2009) complements these by validating SNOT-22 for outcome measurement. Staging in "Staging in rhinosinusitus" by Lund and Mackay (1993) and "Staging for Rhinosinusitis" by Lund and Kennedy (1997) provides foundational severity assessment. "Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52)" by Bachert et al. (2019) applies these in biologic trials.
Paper Timeline
Most-cited paper highlighted in red. Papers ordered chronologically.
Advanced Directions
EPOS guidelines progress from 2012 (Fokkens et al.) to 2020 (Fokkens et al.), focusing on integrated care and biologics amid 72,148 papers. Emphasis remains on inflammation control and surgery, with no recent preprints or news shifting priorities.
Papers at a Glance
| # | Paper | Year | Venue | Citations | Open Access |
|---|---|---|---|---|---|
| 1 | European Position Paper on Rhinosinusitis and Nasal Polyps 2020 | 2020 | Rhinology Journal | 5.4K | ✓ |
| 2 | EPOS 2012: European position paper on rhinosinusitis and nasal... | 2012 | Rhinology Journal | 2.4K | ✕ |
| 3 | A colorimetric method for the determination of glucosamine and... | 1933 | Biochemical Journal | 1.8K | ✓ |
| 4 | Staging in rhinosinusitus. | 1993 | PubMed | 1.5K | ✕ |
| 5 | Psychometric validity of the 22‐item Sinonasal Outcome Test | 2009 | Clinical Otolaryngology | 1.5K | ✕ |
| 6 | Efficacy and safety of dupilumab in patients with severe chron... | 2019 | The Lancet | 1.4K | ✕ |
| 7 | European Position Paper on Rhinosinusitis and Nasal Polyps | 2014 | — | 1.3K | ✓ |
| 8 | EPOS 2012: European position paper on rhinosinusitis and nasal... | 2012 | Rhinology Journal | 1.2K | ✓ |
| 9 | Development and Validation of the Nasal Obstruction Symptom Ev... | 2004 | Otolaryngology | 1.2K | ✕ |
| 10 | Staging for Rhinosinusitis | 1997 | Otolaryngology | 1.1K | ✕ |
Frequently Asked Questions
What are the key recommendations for diagnosing and treating rhinosinusitis and nasal polyps?
The "European Position Paper on Rhinosinusitis and Nasal Polyps 2020" by Fokkens et al. (2020) offers evidence-based guidelines on definitions, classification, diagnosis, and management. It addresses difficult-to-treat rhinosinusitis and integrated care pathways. These recommendations update prior versions from 2012 and 2014.
How is quality of life assessed in chronic rhinosinusitis patients?
"Psychometric validity of the 22‐item Sinonasal Outcome Test" by Hopkins et al. (2009) validates the SNOT-22 as a reliable disease-specific instrument for chronic rhinosinusitis. It modifies the prior SNOT-20 for better psychometric properties in clinical settings. The tool measures health-related quality of life across multiple domains.
What staging systems exist for rhinosinusitis?
"Staging in rhinosinusitus" by Lund and Mackay (1993) introduces a staging method for rhinosinusitis severity. "Staging for Rhinosinusitis" by Lund and Kennedy (1997) refines this for surgical auditing with endoscopy and CT visualization. These systems support treatment planning and outcome evaluation.
What is the role of biologics in severe chronic rhinosinusitis with nasal polyps?
"Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52)" by Bachert et al. (2019) reports positive results from two multicenter phase 3 trials versus placebo. Dupilumab improves symptoms in severe cases. It targets eosinophilic inflammation effectively.
How is nasal obstruction evaluated?
"Development and Validation of the Nasal Obstruction Symptom Evaluation (NOSE) Scale" by Stewart et al. (2004) validates a disease-specific scale for nasal obstruction patients. Tested in adults with septal deformity, it shows strong reliability and validity. The scale aids in assessing surgical outcomes.
What updates do EPOS papers provide on rhinosinusitis?
"EPOS 2012: European position paper on rhinosinusitis and nasal polyps 2012. A summary for otorhinolaryngologists" by Fokkens et al. (2012) summarizes evidence-based updates on definitions, control, and treatments. It builds on 2005 and 2007 papers with new classifications. The 2020 version by Fokkens et al. further revises these guidelines.
Open Research Questions
- ? How can sinus microbiome alterations be targeted to improve outcomes in chronic rhinosinusitis beyond current biologics?
- ? What immunopathologic mechanisms distinguish difficult-to-treat rhinosinusitis subtypes for personalized treatments?
- ? How do endoscopic surgery techniques evolve to optimize quality of life in nasal polyp patients?
- ? Which combinations of treatment guidelines best control eosinophilia in severe cases?
- ? What long-term effects of biologics like dupilumab emerge on sinonasal inflammation and recurrence rates?
Recent Trends
The field holds steady at 72,148 papers with no specified 5-year growth rate.
Core advancements anchor in EPOS updates, from "EPOS 2012" by Fokkens et al. (2389 citations) to "European Position Paper on Rhinosinusitis and Nasal Polyps 2020" by Fokkens et al. (5368 citations), refining diagnostics and biologics integration.
No preprints or news from the last 12 months indicate ongoing reliance on established guidelines like dupilumab trials by Bachert et al. .
2019Research Sinusitis and nasal conditions with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Sinusitis and nasal conditions with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers